Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, a market now led by BeOne’s Brukinsa.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
